Arrowhead Pharmaceuticals, Inc. ((ARWR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arrowhead Pharmaceuticals, Inc. is conducting a clinical study titled A Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-INHBE in Adult Volunteers With Obesity With and Without Diabetes Mellitus. The study aims to assess the safety and effectiveness of ARO-INHBE, a potential treatment for obesity, with a focus on its pharmacokinetics and pharmacodynamics in adults, both with and without type 2 diabetes.
The study is testing ARO-INHBE, an experimental drug delivered via subcutaneous injection, to evaluate its impact on obesity. In Part 2 of the study, ARO-INHBE is combined with tirzepatide, another drug, to further examine its effects.
This interventional study uses a randomized, parallel assignment model with quadruple masking, meaning participants, care providers, investigators, and outcomes assessors are all blinded to the treatment allocations. The primary purpose is to treat obesity and assess the drug’s safety and efficacy.
The study began on November 20, 2024, with primary completion expected in the near future and the last update submitted on September 11, 2025. These dates are crucial as they mark the progress and current status of the study.
The outcome of this study could significantly influence Arrowhead Pharmaceuticals’ stock performance, as successful results may boost investor confidence and position the company favorably against competitors in the obesity treatment market.
The study is ongoing, and further details can be found on the ClinicalTrials portal.